Lecturer
MD 2006
Residency: Nuclear Medicine
Nuclear medicine, Molecular imaging |
|
|
- Radium-223 dichloride 50kBq/Kg versus 80kBq/Kg and versus 50 kBq/Kg in an extended dosing schedule in subjects with castration resistant prostate cancer metastatic to bone. Three arm randomized, phase II study
- Y-90 Clivatuzumab Tetraxetan plus low dose Gemcitabine Versus Placebo plus low dose Gemcitabine in patient with metastatic pancreatic adenocarcinoma. Double blind, randomized phase III.
- Radium -223 dichloride in combination with abiraterone acetate and prednisone in the treatment of asymptomatic or mildly symptomatic chemotherapy na?ve subjects with bone predominant metastatic castration resistant prostate cancer. Double blind, randomized phase III
- A phase II randomized, double blind, placebo-controlled trial of Radium-223 dichloride in combination with exemestane and everolimus versus placebo in combination with exemestane and everolimus when administrated to metastatic HER2 negative hormone receptor positive breast cancer subjects with bone metastasis.
Publications and funding summary / representative publications and grants
- D. Levin, A .Shalev, S. Lantsberg; PET CT of a 54 Y/o patient with Angiosarcoma of liver and a cardiac finding. Volume 155, issue No 4, pages 247-248 April 2016
Suggested multi-disciplinary research project / research focus topics
- Nuclear medicine – all fields